HOOK (HOOKIPA Pharma) Stock Based Compensation: $1.63 Mil (TTM As of Jun. 2025)


HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
View Full Analysis

What is HOOKIPA Pharma Stock Based Compensation?

HOOKIPA Pharma HOOK 50 Stock Based Compensation is $1.63 Mil as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100.

HOOKIPA Pharma's Stock Based Compensation for the three months ended in Jun. 2025 was $0.18 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2025 was $1.63 Mil.

HOOKIPA Pharma Stock Based Compensation Related Terms

HOOKIPA Pharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma Stock Based Compensation Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial 8.66 7.64 5.04 2.35 2.01

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.94 0.87 -0.35 0.18
HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.63 Mil.

What does a Stock Based Compensation of $1.63 Mil mean?
HOOKIPA Pharma (HOOK) has a Stock Based Compensation of $1.63 Mil as of Jun. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for HOOKIPA Pharma and its competitors.
Is HOOKIPA Pharma's Stock Based Compensation too high?
HOOKIPA Pharma's current Stock Based Compensation is $1.63 Mil. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Stock Based Compensation compare to COCP and LNAI?
HOOKIPA Pharma's Stock Based Compensation of $1.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Stock Based Compensation is $1.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current Stock Based Compensation of $1.63 Mil. The current Stock Based Compensation is $1.63 Mil. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Stock Based Compensation is $1.63 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price